1 Corporate Drive
South San Francisco, CA 94080
Cardiologist Yerem Yeghiazarians, MD, and molecular cancer biologist Kurosh Ameri, PhD founded Soley Therapeutics in 2020, but their unique cardio-oncological interdisciplinary collaboration spans more than a decade. Together they built a proprietary understanding of how cells sense stress and respond to molecules or drugs, which in turn dictates cell fate.
The study of cells as biosensors is increasingly recognized as a critical component of our understanding and treatment of diseases. Two Nobel Prizes were awarded in this field for the discovery of different cellular sensing pathways in 2019 and 2021 respectively.
Kurosh Ameri pioneered research of the role of anoxia in disease, and of how cells sense oxygen and differentiate between hypoxia and anoxia.
1998 – 2003
Anoxia is recognized as a widespread phenomenon with oncological and non-oncological implications, indicating commonalities across an array of diseases.
Yerem Yeghiazarians and Kurosh Ameri began their interdisciplinary work at UCSF in generating a proprietary understanding of how cells sense and respond to their environments when exposed to molecules or drugs, thus determining their fate.
Yerem Yeghiazarians and Kurosh Ameri produced numerous proof-of-concept publications and patents.
Yeghiazarians’ and Ameri’s platform technology was fully validated, supported by publications.
Yeghiazarians and Ameri licensed their platform technology and launched Soley Therapeutics with a team of leading experts in biopharma, technology, and business.
Within just 14 months, Soley Therapeutics discovered three patentable novel chemical entities and has a pipeline of 50+ active compounds in the discovery stage.
By combining their interdisciplinary expertise and the power of AI/ML, they developed two end-to-end fully integrated automation units for high-throughput compound evaluation using the cell as a sensor.
Through their groundbreaking work, the team at Soley Therapeutics is able to discover and develop drugs with unparalleled efficiency.
Soley Therapeutics is expanding their team of business experts, scientists, and AI/ML engineers who are revolutionizing the drug discovery and development process.
The study of cells as biosensors is increasingly recognized as a critical component of our understanding and treatment of diseases.
Kaelin (Harvard), Ratcliffe (Oxford), Semenza (Hopkins)
Discovery of how cells sense and respond to oxygen availability
*Soley CSO Kurosh Ameri was a key collaborator during his PhD research (Oxford, CRUK Molecular Oncology Laboratories, Adrian Harris Lab)
Julius (UCSF), Patapoutian (Scripps)
Discovery of how cells sense and respond to temperature, pressure, and touch
Research by Yerem Yeghiazarians, MD, and Kurosh Ameri, PhD has led to several publications and patents before the founding of Soley Therapeutics, which has validated their platform technology and informed the intellectual foundation of their company.
Co-Founder, CEO, Board Member